We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Why Do Early Ovarian Cancer Detection Tests Fail?

By LabMedica International staff writers
Posted on 04 Aug 2009
Current diagnostic tests for ovarian cancer are ineffective for early detection of the disease.

A study has found that in order to significantly lower the mortality rate for the ovarian cancer, tests need to detect tumors about 200-times smaller in mass than those currently used to assess potential new tests. More...
However, the window of opportunity for treating these clinically undetectable cancers before they become life threatening is surprisingly long: about four years.

However, it is also difficult to design an effective test for this disease because there is more than one type of ovarian cancer. The most deadly, known as serous ovarian cancer, accounts for about 50 % of all cases of ovarian cancer and is responsible for at least 80 % of deaths from the disease. In contrast to other types of ovarian tumors, which can grow to be quite large before spreading to other locations, serous ovarian tumors usually metastasize before they are diagnosed.

In its early stages symptoms of ovarian cancer are vague, and often do not occur until the tumor is already several centimeters in diameter. At this point, it may have already spread to surrounding organs and tissues. Several studies have indicated that the current screening tests deliver many false-positive results and do not reduce mortality from the disease.

Biochemistry professor Patrick Brown, M.D., Ph.D. at the Stanford University, school of medicine, (Stanford, CA, USA) and team, which included scientists from the nonprofit Canary Foundation (Palo Alto, CA, USA), performed the study on early detection of ovarian cancer.

The Canary foundation is dedicated to the early detection of many types of cancer. "We are miles away from detecting the most deadly ovarian tumors at this early stage," said Prof. Brown "but now we have a chance of actually designing an effective test that will allow us to treat them before they become deadly."

Prof. Brown added that if a blood test were to be effective it would probably require identifying new markers that are not produced by normal cells. Other possible strategies might rely on new molecular imaging methods, or fluid samples from the uterus or vagina--in which tumor markers are likely to be more concentrated.

The early detection of ovarian cancer study was published in the July 28, 2009 issue of the open-access journal PLoS Medicine.

Related Links:

Stanford University, School of medicine
Canary Foundation
PLoS Medicine



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Immunofluorescence Analyzer
IFA System
New
Slide Scanner System
NanoZoomer S540MD
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers from the Department of Chemistry at Aarhus University have developed and tested a new technology that can identify and measure the concentration of pharmaceuticals in under 10 minutes. Today, this process takes up to an hour. That is critical waiting time for patients suffering from a stroke. (Image Credit: Aarhus University)

Point-of-Care Blood Test Could Speed Treatment Decisions in Acute Stroke

Minutes can shape treatment decisions in emergency stroke care, particularly when physicians need to know whether a patient is taking anticoagulants before administering clot-dissolving therapy.... Read more

Microbiology

view channel
Image: The clearance also broadens QIAstat-Dx\'s infectious disease testing menu in the U.S., which already includes panels for respiratory and gastrointestinal infections, as well as meningitis and encephalitis (Photo courtesy of Qiagen)

One-Hour Molecular Panel Expands Bloodstream Infection Testing for Gram-Negative Pathogens

Bloodstream infections can progress rapidly and lead to sepsis, organ failure, and death. In the United States, about 1.7 million adults develop sepsis each year, and at least 350,000 die during hospitalization... Read more

Industry

view channel
Image

Collaboration Combines AI Cognitive Assessment and RNA Blood Testing for Earlier Alzheimer’s Detection

Alzheimer’s disease is often identified only after substantial neurodegeneration, partly because current diagnostic pathways are fragmented and difficult to scale. As treatment shifts toward earlier intervention,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.